<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01304303</url>
  </required_header>
  <id_info>
    <org_study_id>CLR_10_23</org_study_id>
    <nct_id>NCT01304303</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Advanced Research Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Advanced Research Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I study of SPARC1023 alone and in combination with carboplatin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacokinetic profile and dose escalation study of SPARC1023 when administered as 30-min
      infusion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of MTD</measure>
    <time_frame>One 21-day treatment cycle</time_frame>
    <description>MTD for SPARC1023 in combination with carboplatin will be determined. MTD will be defined as the SPARC1023 dose below the dose at which DLT (Dose Limiting Toxicity) is seen for ≥ 2 subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Establishing the pharmacokinetic profile</measure>
    <time_frame>One 21-day treatment cycle</time_frame>
    <description>Plasma levels of SPARC1023 and Carboplatin will be determined and PK parameters viz. Cmax, AUC0-t, AUC 0-∞, MRT, Tmax, t½ , Kel, Vd for SPARC1023 in combination with carboplatin will be evaluated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Solid Tumor in Advanced Stage</condition>
  <arm_group>
    <arm_group_label>SPARC1023 I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SPARC1023 II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC1023 I</intervention_name>
    <description>IV administration</description>
    <arm_group_label>SPARC1023 I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC1023 II</intervention_name>
    <description>IV administration</description>
    <arm_group_label>SPARC1023 II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  ECOG Performance Status ≤ 1.

          -  Estimated life expectancy of at least 12-weeks;

          -  Measurable disease as per RECIST guideline (Version 1.1);

        Exclusion Criteria:

          -  Any malignancy within past 5-years, except non-melanoma skin cancer, cervical
             intraepithelial neoplasia, or in situ cervical cancer

          -  Known hypersensitivity to the study drugs

          -  Treatment with any anti-cancer agents within 28 days of study entry

          -  Presence of clinically evident active CNS metastases, including leptomeningeal
             involvement, requiring steroid or radiation therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SPARC Site 1</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2011</study_first_submitted>
  <study_first_submitted_qc>February 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2011</study_first_posted>
  <last_update_submitted>October 20, 2016</last_update_submitted>
  <last_update_submitted_qc>October 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid</keyword>
  <keyword>tumor</keyword>
  <keyword>taxane</keyword>
  <keyword>platinum</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

